S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

BeyondSpring Stock Forecast, Price & News

-0.08 (-0.61 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $12.98
50-Day Range
MA: $13.60
52-Week Range
Now: $12.98
Volume306,133 shs
Average Volume317,561 shs
Market Capitalization$508.06 million
P/E RatioN/A
Dividend YieldN/A
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
BeyondSpring logo


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BYSI
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$1.12 per share


Net Income$-38,080,000.00


Market Cap$508.06 million
Next Earnings Date4/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.22 out of 5 stars

Medical Sector

817th out of 1,962 stocks

Pharmaceutical Preparations Industry

397th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.08 (-0.61 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

Is BeyondSpring a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BeyondSpring stock.
View analyst ratings for BeyondSpring
or view top-rated stocks.

What stocks does MarketBeat like better than BeyondSpring?

Wall Street analysts have given BeyondSpring a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BeyondSpring wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BeyondSpring?

BeyondSpring saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,150,000 shares, an increase of 16.5% from the December 31st total of 987,500 shares. Based on an average daily trading volume, of 462,500 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.5% of the company's shares are sold short.
View BeyondSpring's Short Interest

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for BeyondSpring

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.54) by $0.06.
View BeyondSpring's earnings history

How has BeyondSpring's stock been impacted by COVID-19?

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BYSI stock has increased by 14.4% and is now trading at $12.98.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BYSI?

4 analysts have issued 12 month target prices for BeyondSpring's shares. Their forecasts range from $25.00 to $43.00. On average, they expect BeyondSpring's share price to reach $32.67 in the next year. This suggests a possible upside of 151.7% from the stock's current price.
View analysts' price targets for BeyondSpring
or view top-rated stocks among Wall Street analysts.

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the following people:
  • Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 50)
  • Ms. Elizabeth Adkins Czerepak, Chief Financial Officer (Age 65)
  • Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 60)
  • Dr. James R. Tonra Ph.D., Chief Scientific Officer (Age 55)
  • Stephen Kilmer, Head of Investor Relations
  • Mr. Gregg Russo, Sr. VP of HR
  • Dr. Ramon W. Mohanlal, Exec. VP of R&D, Chief Medical Officer and Director (Age 63)
  • Dr. G. Kenneth Lloyd, Chief Scientific Advisor (Age 77)
  • Dr. Gordon L. Schooley, Chief Regulatory Officer (Age 74)
  • Mr. Dongheng Liu, Chief Financial Officer of BeyondSpring-China (Age 39)

Who are some of BeyondSpring's key competitors?

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an IPO on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

Who are BeyondSpring's major shareholders?

BeyondSpring's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (7.04%), BlackRock Inc. (3.04%), Northern Trust Corp (0.64%), Nuveen Asset Management LLC (0.31%), Renaissance Technologies LLC (0.32%) and Blair William & Co. IL (0.24%).

Which major investors are selling BeyondSpring stock?

BYSI stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, and Barclays PLC.

Which major investors are buying BeyondSpring stock?

BYSI stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., Nuveen Asset Management LLC, Endurance Wealth Management Inc., Renaissance Technologies LLC, Laurion Capital Management LP, Blair William & Co. IL, and JPMorgan Chase & Co..

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $12.98.

How much money does BeyondSpring make?

BeyondSpring has a market capitalization of $508.06 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does BeyondSpring have?

BeyondSpring employs 61 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

Where are BeyondSpring's headquarters?

BeyondSpring is headquartered at 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.